SpyGlass Pharma reported new 18-month data showing that its intraocular lens (IOL)–based drug delivery platform significantly improved visual acuity and reduced intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. The results were presented by Marco A. Robles, MD, at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting in Los Angeles.

In the single-center first-in-humans study of 23 patients undergoing cataract surgery, all participants received the SpyGlass device. Best corrected distance visual acuity improved from a range of 20/30 to 20/100 at baseline to 20/16 to 20/30 at 18 months. Mean IOP dropped from 25.1 mmHg to 14.1 mmHg, with all patients remaining off topical IOP-lowering medications. No product-related adverse events were observed.

The SpyGlass platform delivers bimatoprost over 3 years via a lens implant, offering a potential alternative to daily eye drops. SpyGlass has completed enrollment for a phase 1/2 study in the United States and plans to advance into phase 3 trials pending further data.

SpyGlass Pharma was cofounded by Dr. Malik Kahook and Glenn Sussman, based on technology developed at the University of Colorado School of Medicine. GP